Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 4/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 5/20 | 0.36 |
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291155 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2TDP1POLBRAB9AKDM4E | |
| SCHEMBL4291731 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2TDP1POLBRAB9AKDM4E | |
| SCHEMBL4284630 | 0.83 | CNR2 (0.35) | GRNSORT1CNR1CNR2KDM4E | |
| SCHEMBL4286066 | 0.82 | RAB9A (0.35) | SMN1; SMN2TDP1POLBRAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL4284926 | 0.81 | GRN (0.36) | GRNSORT1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL4288567 | 0.80 | FAAH (0.34) | SMN1; SMN2POLBKMT2AMAPT | |
| SCHEMBL4290844 | 0.74 | PIK3CD (0.35) | SMN1; SMN2POLBRAB9AKDM4EALDH1A1 | |
| SCHEMBL4281250 | 0.74 | KDM4E (0.46) | POLBKDM4EALDH1A1KMT2ALMNA | |
| SCHEMBL3995561 | 0.72 | GRN (0.46) | GRNSORT1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL4292395 | 0.72 | ALDH1A1 (0.47) | SMN1; SMN2POLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GRN 3093/4885SORT1 3316/4885CNR1 3488/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GRN 3093/4885SORT1 3316/4885CNR1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.